SS-31

SS-31 (elamipretide/Bendavia) is a synthetic mitochondria-targeted tetrapeptide developed by Szeto and Schiller. Its alternating aromatic-cationic motif (D-Arg-Dmt-Lys-Phe) enables it to concentrate >1000-fold in the inner mitochondrial membrane, where it binds cardiolipin, a phospholipid unique to mitochondria. Cardiolipin is critical for the structural organization and function of electron transport chain complexes and their supercomplexes. SS-31 has been investigated in clinical trials for multiple conditions involving mitochondrial dysfunction, including heart failure, kidney disease, and primary mitochondrial myopathy. The peptide’s D-arginine and dimethyltyrosine modifications confer resistance to proteolysis. SS-31 does not collapse the mitochondrial membrane potential (unlike uncouplers) — instead, it optimizes electron transport chain function by stabilizing cardiolipin interactions with respiratory complexes.

SS-31 has been investigated for its selective binding to cardiolipin in the inner mitochondrial membrane. Cardiolipin is a tetra-acyl phospholipid essential for the structural integrity and catalytic function of electron transport chain complexes, particularly Complex III (cytochrome bc1) and Complex IV (cytochrome c oxidase), and for the formation of respiratory supercomplexes. Researchers observed that SS-31 binds cardiolipin through electrostatic and hydrophobic interactions, stabilizing the lipid’s interaction with respiratory complexes and improving electron transfer efficiency. Studies suggest that this stabilization reduces electron leak to oxygen at Complex I and Complex III, decreasing superoxide production. In heart failure models, researchers observed that SS-31 restored respiratory supercomplex organization disrupted by cardiolipin oxidation and remodeling. Additionally, SS-31 facilitates cytochrome c interactions with cardiolipin, maintaining the electron carrier’s function while preventing its conversion to a cardiolipin peroxidase. The peptide concentrates in mitochondria driven by the membrane potential, achieving therapeutic concentrations at its site of action.

Cardiolipin Binding

Birk et al. (2013) characterized SS-31’s interaction with cardiolipin and demonstrated that the peptide stabilizes cardiolipin-dependent respiratory complex organization, improving electron transport chain efficiency [1].

Heart Failure

Sabbah et al. (2016) investigated elamipretide in a canine heart failure model and observed improved mitochondrial function, cardiac energetics, and left ventricular function following chronic treatment [2].

Mitochondrial Medicine

Szeto HH (2014) reviewed the development of mitochondria-targeted peptides and described SS-31’s unique mechanism of action through cardiolipin binding rather than membrane depolarization [3].